Previous studies indicate that CD99 is a marker of stem cells in acute myeloid leukemia (AML) and myelodysplastic syndrome, and is also a marker for prospective separation of leukemic stem cells (LSCs) from functionally normal hematopoietic stem cells in AML [49]. This evidence concerns the gene CD99 and myelodysplastic syndrome.